Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Morningstar brands and products Company Portfolio ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Head and neck cancer patients went disease-free for five years, compared to half that time for people undergoing standard ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

today announced that a poster was presented over the weekend at the 39 th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention ...

Researchers are praising the results of two studies that used immunotherapy to fight one of the most difficult-to-treat types of brain cancer, glioblastoma. The studies used CAR-T therapy, which uses ...

Media: Jeffrey Krasner Slowey McManus Communications jkrasner@sloweymcmanus.com +1 (617) 840-9806 Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to ...

The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer ...

today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

Society for Immunotherapy of Cancer (SITC) 2023 poster. 3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced ...